Article Text

PDF
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
  1. C Bauer1,
  2. F Bauernfeind1,
  3. A Sterzik1,
  4. M Orban1,
  5. M Schnurr1,
  6. H A Lehr3,
  7. S Endres2,
  8. A Eigler1,
  9. M Dauer1
  1. 1Section of Gastroenterology, Medizinische Klinik Innenstadt, University of Munich, Ziemssenstr. 1, 80336 Munich, Germany
  2. 2Division of Clinical Pharmacology, Medizinische Klinik Innenstadt, University of Munich, Ziemssenstr. 1, 80336 Munich, Germany
  3. 3Institut Universitaire de Pathologie, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 25, CH-1011 Lausanne, Switzerland
  1. Correspondence to:
    Dr Marc Dauer
    Medizinische Klinik Innenstadt, University of Munich, Ziemssenstr. 1, 80336 Munich, Germany; marc.dauer{at}med.uni-muenchen.de

Abstract

Background: Tumour-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by vaccination with dendritic cells (DCs). However, clinical responses to DC-based vaccination have only been observed in a minority of patients with solid cancer. Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells. It has been shown previously that gemcitabine sensitises human pancreatic carcinoma cells against CTL-mediated lysis. Here, a murine pancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination.

Methods: Bone marrow-derived DCs from C57BL/6 mice were loaded with UV-irradiated, syngeneic Panc02 carcinoma cells and were administered subcutaneously. For prophylactic vaccination, mice were vaccinated three times at weekly intervals prior to tumour challenge with Panc02 cells. Therapeutic vaccination was started when tumours formed a palpable nodule. Gemcitabine was administered intraperitoneally twice weekly.

Results: Prophylactic DC-based vaccination completely prevented subcutaneous and orthotopic tumour development and induced immunological memory as well as tumour antigen-specific CTLs. In the subcutaneous tumour model, therapeutic DC-based vaccination was equally effective as gemcitabine (14% vs 17% survival at day 58 after tumour challenge; controls, 0%). Combination of the two strategies significantly increased survival of tumour-bearing mice (50% at day 58 after tumour challenge). DC-based vaccination also prevented death from pulmonary metastatisation after intravenous injection of Panc02 cells.

Conclusion: DC-based immunotherapy may not only be successfully combined with gemcitabine for the treatment of advanced pancreatic carcinoma, but may also be effective in preventing local recurrence or metastatisation in tumour-free patients.

  • CD, cluster of differentiation
  • CFSE, carboxyfluorescein diacetate-succinimidyl ester
  • CTL, cytotoxic T lymphocyte
  • DC, dendritic cell
  • DMEM, Dulbecco’s modified Eagle’s medium
  • FACS, fluorescence-activated cell sorting
  • FCS, fetal calf serum
  • 5-FU, 5-fluorouracil
  • GM-CSF, granulocyte–macrophage colony-stimulating factor
  • IFN, interferon
  • IL, interleukin
  • LPS, lipopolysaccharide
  • mAb, monoclonal antibody
  • MHC, major histocompatibility complex
  • MuLV, murine leukaemia virus
  • NK, natural killer
  • TGF, transforming growth factor
  • Th1, T helper type 1
  • TNF, tumour necrosis factor

Statistics from Altmetric.com

Footnotes

  • *These authors contributed equally. This work is part of the doctoral theses of F Bauernfeind and A Sterzik at the University of Munich, Munich, Germany.

  • Published Online First 29 March 2007

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.